Proteomics may unlock key clues to mepolizumab success in rare lung disease
NCT ID NCT07343661
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to find biological markers in blood, saliva, and sputum that can predict how well patients with EGPA (a rare inflammatory disease) and severe asthma respond to the drug mepolizumab. Researchers will analyze proteins in these samples before and after treatment to understand disease progression and treatment effects. The goal is to improve personalized care and potentially use less invasive saliva tests instead of blood draws.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mepolizumab (Nucala)
What this could lead to
If successful, this could identify biomarkers to predict which patients will respond best to mepolizumab, improving personalized treatment for EGPA and severe asthma.
What could go wrong
This is an early-phase observational study focused on biomarkers, not a treatment trial. The findings may not lead to immediate clinical changes or benefit participants directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Policlinico Duilio Casula AOU Cagliari
Cagliari, Cagliari, Italy